Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy

Sponsor
Martha Haahr M.D (Other)
Overall Status
Unknown status
CT.gov ID
NCT02240823
Collaborator
Odense University Hospital (Other)
30
1
1
29
1

Study Details

Study Description

Brief Summary

Prostate cancer is the most common cancer among Danish men, and the incidence is increasing. Studies have shown a high number needed to treat for each saved prostate cancer related death. Since the treatments incur many complications, there is a need to address these. After prostatectomy, 80% experience erectile dysfunction. Sexual life is a central part of people's identity, self-esteem and quality of life. Stem cells have generated a large amount of promising data suggesting that stem cells can alleviate erectile dysfunction, by regenerating nerves as well as endothelial and smooth muscle cells in the corpus cavernous.

Condition or Disease Intervention/Treatment Phase
  • Other: adipose derived stem cells
Phase 1

Detailed Description

Prostate cancer is the most common cancer among Danish men, and the incidence is increasing. Studies have shown a high number needed to treat for each saved prostate cancer related death.

After prostatectomy, 80% experience erectile dysfunction. Sexual life is a central part of people's identity, self-esteem and quality of life. Stem cells have generated a large amount of promising data suggesting that stem cells can alleviate erectile dysfunction, by regenerating nerves as well as endothelial and smooth muscle cells in the corpus cavernous.

Animal studies have used stem cell therapy to improve erectile dysfunction in rats after cavernous nerve damage, with invariable high success rate.

In this pilot study will include 30 patient's with erectile dysfunction 3-9 mdr after prostatectomy. The men have no spontaneous erectile function and no response to drug treatment.

Liposuction is carried out in general anesthesia. Isolation of stem cells will be done simultaneously and the stem cells injected into the corpus cavernous directly after the isolation is carried out.

This is a clinical study evaluating an innovative cell therapy procedure.The objective of this study was to evaluate the effects of injection of stem cell of adipose origin.

The project will run over a period of twelve months. Patients will be followed for a period of six months. Treatment efficacy will be assessed from validated questionnaires.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase 1 Study. Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy
Study Start Date :
Apr 1, 2014
Actual Primary Completion Date :
Oct 1, 2015
Anticipated Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: adipose derived stem cells

Other: adipose derived stem cells

Outcome Measures

Primary Outcome Measures

  1. Safety and Tolerability [1 month after surgery]

    Adverse Events

Secondary Outcome Measures

  1. Improvement in erectile function, measured i IIEF-5 score [1,3,6,9 and 12 months]

    Assessed by interview and questionnaires

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Men who have had prostate removed due to prostate cancer regardless bilateral nerve-sparing, unilateral nerve-sparing or non-nerve-sparing surgical technique.

  • Erectile dysfunction

  • Sexually active/ have sexual interest

  • We make no distinction for the patients are operated with

Exclusion Criteria:
  • Absence of sexual interest.

  • Patients with impaired health condition where anesthesia would be a risk of complications.

  • BMI below 20.

  • Small amount of abdominal fat assessed by. Ct abdomen.

  • Patients on anticoagulant treatment.

  • Men with suspicion of residual tumor.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Odense Universitet Hospital Odense Denmark 5000

Sponsors and Collaborators

  • Martha Haahr M.D
  • Odense University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Martha Haahr M.D, Medical doctor, Odense University Hospital
ClinicalTrials.gov Identifier:
NCT02240823
Other Study ID Numbers:
  • 2013-Afd-L
First Posted:
Sep 16, 2014
Last Update Posted:
Oct 16, 2015
Last Verified:
Oct 1, 2015
Keywords provided by Martha Haahr M.D, Medical doctor, Odense University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 16, 2015